Lipotoxicity and immunometabolism in ischemic acute kidney injury: current perspectives and future directions

Afolarin A. Otunla; Kumaran Shanmugarajah; Alun H. Davies; Joseph Shalhoub

doi:10.3389/fphar.2024.1355674

Frontiers in Pharmacology (Feb 2024)

Lipotoxicity and immunometabolism in ischemic acute kidney injury: current perspectives and future directions

Afolarin A. Otunla,
Kumaran Shanmugarajah,
Alun H. Davies,
Joseph Shalhoub

Affiliations

Afolarin A. Otunla: Department of Surgical Biotechnology, University College London, London, United Kingdom
Kumaran Shanmugarajah: Cleveland Clinic, Cleveland Clinic Transplant Centre, Cleveland, OH, United States
Alun H. Davies: UK and Imperial Vascular Unit, Section of Vascular Surgery, Department of Surgery and Cancer, Imperial College London, Imperial College Healthcare NHS Trust, London, United Kingdom
Joseph Shalhoub: UK and Imperial Vascular Unit, Section of Vascular Surgery, Department of Surgery and Cancer, Imperial College London, Imperial College Healthcare NHS Trust, London, United Kingdom

DOI: https://doi.org/10.3389/fphar.2024.1355674
Journal volume & issue: Vol. 15

Abstract

Read online

Dysregulated lipid metabolism is implicated in the pathophysiology of a range of kidney diseases. The specific mechanisms through which lipotoxicity contributes to acute kidney injury (AKI) remain poorly understood. Herein we review the cardinal features of lipotoxic injury in ischemic kidney injury; lipid accumulation and mitochondrial lipotoxicity. We then explore a new mechanism of lipotoxicity, what we define as “immunometabolic” lipotoxicity, and discuss the potential therapeutic implications of targeting this lipotoxicity using lipid lowering medications.

Published in Frontiers in Pharmacology

ISSN: 1663-9812 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: http://journal.frontiersin.org/journals/pharmacology

About the journal

Abstract

Keywords